Simvastatin in vitiligo: an update with recent review of the literature

Rashidul Hasan; Komal Agarwal; Indrashis Podder; Angelica Misitzis; Robert A. Schwartz; Uwe Wollina; Torello Lotti; Stephan Grabbe; Mohamad Goldust

doi:https://doi.org/10.1111/ijd.15330

Simvastatin in vitiligo: an update with recent review of the literature

Rashidul Hasan, Komal Agarwal, Indrashis Podder, Angelica Misitzis, Robert A. Schwartz, Uwe Wollina, Torello Lotti, Stephan Grabbe, Mohamad Goldust

New Jersey Medical School (NJMS), Medicine, Division of Dermatology

Rutgers, The State University

Research output: Contribution to journal › Review article › peer-review

Abstract

Patients with vitiligo often seek medical attention, as it diminishes their quality of life resulting in significant morbidity. Several topical and systemic therapies are in vogue targeting the immunological aspect of this disease, but results are often unsatisfactory, and complete cure remains elusive. Recently, simvastatin, a 3-hydroxy-3-methylyglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, is being evaluated for vitiligo management because of its multimodal action, easy availability, and low cost. The proposed multimodal actions range from anti-inflammatory, antioxidant, to immunomodulatory properties which may be of therapeutic benefit in vitiligo patients. The authors intend to evaluate the role of simvastatin as a novel therapeutic agent for vitiligo along with relevant review of literature.

Original language	American English
Pages (from-to)	e390-e396
Journal	International journal of dermatology
Volume	60
Issue number	10
DOIs	https://doi.org/10.1111/ijd.15330
State	Published - Oct 2021

ASJC Scopus subject areas

Dermatology

Access to Document

https://doi.org/10.1111/ijd.15330

Cite this

@article{9bd766ed389340249745d42064464003,

title = "Simvastatin in vitiligo: an update with recent review of the literature",

abstract = "Patients with vitiligo often seek medical attention, as it diminishes their quality of life resulting in significant morbidity. Several topical and systemic therapies are in vogue targeting the immunological aspect of this disease, but results are often unsatisfactory, and complete cure remains elusive. Recently, simvastatin, a 3-hydroxy-3-methylyglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, is being evaluated for vitiligo management because of its multimodal action, easy availability, and low cost. The proposed multimodal actions range from anti-inflammatory, antioxidant, to immunomodulatory properties which may be of therapeutic benefit in vitiligo patients. The authors intend to evaluate the role of simvastatin as a novel therapeutic agent for vitiligo along with relevant review of literature.",

author = "Rashidul Hasan and Komal Agarwal and Indrashis Podder and Angelica Misitzis and Schwartz, {Robert A.} and Uwe Wollina and Torello Lotti and Stephan Grabbe and Mohamad Goldust",

note = "Publisher Copyright: {\textcopyright} 2021 the International Society of Dermatology",

year = "2021",

month = oct,

doi = "https://doi.org/10.1111/ijd.15330",

language = "American English",

volume = "60",

pages = "e390--e396",

journal = "International journal of dermatology",

issn = "0011-9059",

publisher = "Wiley-Blackwell",

number = "10",

}

TY - JOUR

T1 - Simvastatin in vitiligo

T2 - an update with recent review of the literature

AU - Hasan, Rashidul

AU - Agarwal, Komal

AU - Podder, Indrashis

AU - Misitzis, Angelica

AU - Schwartz, Robert A.

AU - Wollina, Uwe

AU - Lotti, Torello

AU - Grabbe, Stephan

AU - Goldust, Mohamad

PY - 2021/10

Y1 - 2021/10

N2 - Patients with vitiligo often seek medical attention, as it diminishes their quality of life resulting in significant morbidity. Several topical and systemic therapies are in vogue targeting the immunological aspect of this disease, but results are often unsatisfactory, and complete cure remains elusive. Recently, simvastatin, a 3-hydroxy-3-methylyglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, is being evaluated for vitiligo management because of its multimodal action, easy availability, and low cost. The proposed multimodal actions range from anti-inflammatory, antioxidant, to immunomodulatory properties which may be of therapeutic benefit in vitiligo patients. The authors intend to evaluate the role of simvastatin as a novel therapeutic agent for vitiligo along with relevant review of literature.

AB - Patients with vitiligo often seek medical attention, as it diminishes their quality of life resulting in significant morbidity. Several topical and systemic therapies are in vogue targeting the immunological aspect of this disease, but results are often unsatisfactory, and complete cure remains elusive. Recently, simvastatin, a 3-hydroxy-3-methylyglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, is being evaluated for vitiligo management because of its multimodal action, easy availability, and low cost. The proposed multimodal actions range from anti-inflammatory, antioxidant, to immunomodulatory properties which may be of therapeutic benefit in vitiligo patients. The authors intend to evaluate the role of simvastatin as a novel therapeutic agent for vitiligo along with relevant review of literature.

UR - http://www.scopus.com/inward/record.url?scp=85100560743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100560743&partnerID=8YFLogxK

U2 - https://doi.org/10.1111/ijd.15330

DO - https://doi.org/10.1111/ijd.15330

M3 - Review article

C2 - 33554328

SN - 0011-9059

VL - 60

SP - e390-e396

JO - International journal of dermatology

JF - International journal of dermatology

IS - 10

ER -

Simvastatin in vitiligo: an update with recent review of the literature

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this